Wednesday, April 11, 2007
WaveLight's Allegretto Wave LASIK technology is approved in the United States for the correction of the following refractive errors:
Wavefront-guided Allegretto Wave:
Up to -7.00 D of myopia
Up to -3.00 D of myopic astigmatism
Wavefront-optimized Allegretto Wave:
Up to -12.00 D of myopia
Up to -6.00 D of myopic astigmatism
Up to +6.00 D of hyperopia
Up to +5.00 D of hyperopic astigmatism
Results of clinical trials
Approval of WaveLight's Allegretto Wave technology for LASIK surgery in the United States is based on the results of clinical trials of the company's wavefront-optimized procedure mandated by the U.S. Food and Drug Administration (FDA).
In the clinical trial for the correction of nearsightedness, uncorrected visual acuity (UCVA) results 3 months after surgery were:
84.4% of the eyes were 20/20 or better.
98.0% of eyes were 20/40 or better.
In the clinical trial for the correction of farsightedness (with and without astigmatism) UCVA results 6 months after surgery were:
67.5% of the eyes were 20/20 or better.
95.3% of the eyes were 20/40 or better.
To learn more about WaveLight's Allegretto Wave LASIK technology, visit